Differential Modeling of Fragile X Syndrome by Human Embryonic Stem Cells and Induced Pluripotent Stem Cells  by Urbach, Achia et al.
Cell Stem Cell
Brief ReportDifferential Modeling of Fragile X Syndrome
by Human Embryonic Stem Cells
and Induced Pluripotent Stem CellsAchia Urbach,1,2,4 Ori Bar-Nur,3,4 George Q. Daley,1,2,* and Nissim Benvenisty3,*
1Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Manton Center for Orphan Disease Research,
Howard Hughes Medical Institute, Children’s Hospital Boston and Dana Farber Cancer Institute; Division of Hematology, Brigham and
Women’s Hospital, Boston, MA 02115, USA
2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Harvard Stem Cell Institute, Boston,
MA 02115, USA
3Stem Cell Unit, Department of Genetics, Institute of Life Sciences, The Hebrew University, Jerusalem 91904, Israel
4These authors contributed equally to this work
*Correspondence: george.daley@childrens.harvard.edu (G.Q.D.), nissimb@cc.huji.ac.il (N.B.)
DOI 10.1016/j.stem.2010.04.005In embryonic stem cell (ESC) lines gener-
ated from human embryos determined
through preimplantation genetic diag-
nosis to carry the fragile X mutation, the
FMR1 gene is expressed in undifferenti-
ated cells but undergoes transcriptional
silencing after ESC differentiation (Eiges
et al., 2007). Here, we generated induced
pluripotent stem cell (iPSC) lines from
fibroblasts of individuals carrying the frag-
ile X mutation. Despite successful reprog-
ramming of the somatic cells to pluripo-
tency, the FMR1 gene remained inactive
and carried DNA methylation and his-
tone modifications indicative of inactive
heterochromatin. These data highlight
critical differences between ESCs and
iPSCs in modeling fragile X disorder.
Pluripotent stem cells are potentially an
important tool to model human genetic
disorders. Human embryonic stem cells
can recapitulate early stages of human
development, and they can also differen-
tiate into cells from the three embryonic
germ layers (Schuldiner et al., 2000;
Thomson et al., 1998). Thus, human plu-
ripotent stem cells can be used to analyze
the effect of specific mutations on the
differentiation of various cell types and
on early developmental processes that
are otherwise inaccessible for research.
In the past few years, several diseases
have been modeled in pluripotent stem
cells, either by direct gene mutagenesis
or by deriving ESCs from embryos deter-
mined by preimplantation genetic diag-
nosis (PGD) to carry genetic mutation
(Eiges et al., 2007; Urbach et al., 2004;
reviewed in Lengerke and Daley, 2009).
Recently, human pluripotent stem cells
have been derived from somatic cells byintroduction of defined factors (Lowry
et al., 2008; Park et al., 2008c; Takahashi
et al., 2007; Yu et al., 2007). These
induced pluripotent stem cells (iPSCs)
show remarkable similarity to human
ESCs (Lowry et al., 2008; Park et al.,
2008c; Takahashi et al., 2007; Yu et al.,
2007). By reprogramming somatic cells
from patients, one may isolate pluripotent
cells that harbor disease-specific muta-
tions (Park et al., 2008a). The reprogram-
ming of somatic cells into pluripotent cells
raised the question whether iPSCs will be
able to replace human ESCs in basic
research as well as in clinical applications
(Belmonte et al., 2009). We are now in
a unique position to compare disease
phenotypes manifest in ESCs to those
seen in iPSCs.
Fragile X (FX) syndrome is the most
common form of inherited mental retarda-
tion (Crawford et al., 2001; Rousseau
et al., 1992). It is caused by the absence
of expression of the fragile X mental retar-
dation 1 (FMR1) gene (O’Donnell and
Warren, 2002). The vast majority of FX
patients do not express FMR1 resulting
from CGG triplet repeat expansion in the
50 untranslated region of the gene (Pear-
son et al., 2005; Verkerk et al., 1991).
Full expansion of the CGG repeat usually
coincides with hypermethylation of the
repeat region and its upstream promoter
(Oberle et al., 1991), and with chromatin
modifications such as histone H3 tail
deacetylation, histone H3K9 methylation,
and histone H3K4 demethylation (Coffee
et al., 1999). Until recently, early events
in FMR1 silencing could not be character-
ized because of the lack of an appropriate
animal model (Bontekoe et al., 1997;Cell Stem CLavedan et al., 1997), but human ESCs
have now been derived from FX blasto-
cysts determined through preimplanta-
tion genetic diagnosis (PGD) (Eiges
et al., 2007). In the undifferentiated FX-
ESCs, the full expansion of the CGG triplet
repeat is not sufficient to inactivate the
expression of the FMR1 gene and gene
silencing occurs only upon differentiation
(Eiges et al., 2007). Evidence from cho-
rionic villus samples supports a similar
conclusion that transcriptional silencing
of the FMR1 gene occurs with human
development (Sutcliffe et al., 1992;
Willemsen et al., 2002). Current data
suggest that upon cell differentiation, the
mutated FMR1 gene recruits specific his-
tone modifications followed by DNA meth-
ylation, which silence its transcription
(Eiges et al., 2007; Pietrobono et al., 2005).
In the current study we have isolated
iPSC lines from three FX affected males
and compared the regulation of FMR1
transcription to that of human FX-ESCs.
Fibroblasts from 4-year-old and 28-year-
old individuals, as well as fetal-lung fibro-
blasts from a 22-week-old affected fetus
with FX syndrome, were reprogrammed
in culture according to published proto-
cols (Park et al., 2008b; Takahashi et al.,
2007). The efficiency of reprogramming
of the FX-fibroblasts was similar to
that of the WT-fibroblasts (0.0056% and
0.0024%, respectively), as determined by
counting the number of Tra-1-60-positive
colonies. Multiple FX-iPSC clones were
analyzed (seven from the first, two from
the second, and two from the third
patient). The iPSC clones demonstrated
typical characteristics of pluripotent stem
cells: morphology similar to that of ESCsell 6, May 7, 2010 ª2010 Elsevier Inc. 407
Figure 1. FMR1 Expression in FX-iPSCs
(A) FMR1 transcript expression as analyzed by real-time PCR in FX-ESCs, normal ESCs, normal fibroblasts, 2 normal iPSC clones, FX-fibroblasts from 3 different
patients (A, B, C), and 11 FX-iPS cell clones derived from the FX-fibroblasts. Shown are FMR1 relative expression levels with their respective standard errors.
(B) Comparison of FMR1 expression levels (with their respective standard errors) in two FX-iPSC clones at low passage (p5) and high passage (p17 and p18).
(C) Immunostaining for FMRP in ESCs, iPSCs, FX-ESCs, and FX-iPSCs by using goat anti-human FMRP antibody and Hoechst 33258 for nuclear staining.
(D) FMR1 and NANOG expression levels (with their respective standard errors) in FX-ESCs, Diff-FX-ESCs (a population of cells differentiated from FX-ESCs), and
Diff-FX-ESC-iPSCs (iPSCs derived from differentiated FX-ESCs).
(E) Analysis of CGG repeat number in Diff-FX-ESC, Diff-FX-ESC-iPSC clones #2 and #6, two samples of FX-ESCs, and two subclones of the FX-ESCs. Note that
the Diff-FX-ESC and the FX-ESC represent cell populations that are heterogeneous with respect to CGG repeat number (Eiges et al., 2007), whereas in the Diff-
FX-ESC-iPSC and the FX-ESC subclones, a dominant band indicates the more homogenous population expected in subclones. The size of the DNA marker
bands is in base pairs and the number of the CGG repeats are shown at the left and right sides of the gel, respectively.
For further characterization of the undifferentiated iPSC clones and their pluripotency see also Figures S1 and S2.
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Tra-1-60, OCT4, SOX2, NANOG, SSEA3,
SSEA4, and Tra-1-81 (Figure S1A avail-
able online); silencing of retroviral trans-
genes (Figure S1B and data not shown);
reactivation of genes indicative of pluripo-
tency (Figures S1C and S1D and data not
shown); and maintenance of a normal
diploid karyotype (Figure S1E). By hierar-
chical clustering and scatter plot analysis
of DNA microarray results, we observed
that the iPSCs cluster together with
human ESCs and apart from their cell of
origin (Figures S2A and S2B). The cells
generated embryoid bodies (Figure S2C,
I) that expressed markers of endoderm
(Figure S2C, II and III), mesoderm (Fig-
ure S2C, IV and V), and ectoderm408 Cell Stem Cell 6, May 7, 2010 ª2010 Els(Figure S2C, VI) as demonstrated by im-
munostaining and also by RT-PCR (data
not shown). The iPSC lines also differenti-
ated in vivo into teratomas that manifest
elements of all embryonic germ layers
(Figure S2D). Thus, these human iPSC
lines met stringent criteria for pluripotency
(Chan et al., 2009; Daley et al., 2009).
The FMR1 gene is expressed in FX-
ESCs, WT-ESCs, wild-type skin fibro-
blasts, and iPSCs derived from them (Fig-
ure 1A). The FMR1 gene is also expressed
in wild-type lung fibroblasts (MRC5) and
iPSCs derived from them (data not
shown). In marked contrast to all of these
cells, the FMR1 gene remained tran-
scriptionally silent in all FX-iPSC clones
derived from skin or lung FX-fibroblastsevier Inc.(Figure 1A). These results suggest that the
differences in the expression of FMR1
between the WT and FX-iPSCs are due
to the FMR1 mutation and not due to the
tissue source of the original fibroblasts.
The absence of FMR1 gene expression
in the FX-iPSCs was observed both in
early passage (P5) and at higher passages
(up to P18; Figure 1B), indicating a stable
phenotype. The FX-iPSCs also lacked
expression of the FMR1 protein by immu-
nostaining (Figure 1C).
Downregulation of the FMR1 gene
occurs upon differentiation of human FX-
ESCs, concomitant with downregulation
of pluripotency-associated genes such
as NANOG (Figure 1D; Eiges et al.,
2007). Interestingly, when differentiated
Figure 2. Epigenetic Modifications in FX-iPSCs
(A) Pyrosequencing analysis of the FMR1 promoter in WT-fibroblasts, two clones of WT-iPSCs (iPS 28, iPS 94), FX-fibroblasts-A, and seven derivative iPSC lines
(FX-iPS A-12, 17, 47, 50, 52, 55, 89), FX-fibroblasts-C and two derivative iPSC lines (FX-iPS C-2, C-3). Top: methylation level at CpG position. Bottom: average
methylation level of all CpG sites for each sample with their respective standard errors.
(B) Bisulfite sequencing analysis of the OCT4 promoter in FX-fibroblasts-A and FX-iPSC clones derived from them. Open circles, unmethylated CpGs; black
circles, methylated CpGs.
(C) Pyrosequencing analysis of the OCT4 50UTR in FX-fibroblasts-C and FX-iPSC clones derived from them.
(D) Histone modifications at the FMR1 locus in FX-iPSCs: ChIP analysis of histone H3-tail acetylation and H3K4 and H3K9 methylation in FX-iPSCs. Real-time
PCR was performed on bound and input sonicated DNA fragments with primers for the FMR1 promoter. Adenine phosphoribosyl transferase (APRT) and Crys-
talline (CRYST) served as positive and negative controls, respectively. Values were normalized to the appropriate positive control and shown with their respective
standard errors.
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to pluripotency by introduction of the
reprogramming factors OCT4/SOX2/c-
MYC/KLF4, they also failed to reactive
FMR1 expression (Figure 1D). The CGG
repeat length in the iPSCs derived from
the differentiated FX-ESCs is in the
same range as the FX-ESCs and the two
subclones of FX-ESCs (Figure 1E). The
data suggest that the silencing of the
FMR1 in the FX-iPSCs is not due to
expansion of the CGG repeats above
that observed in FX-ESCs, where the
gene is still active. The data also indicate
that the reprogramming process has nomajor effect on the instability of the CGG
repeats, because the reprogrammed cells
have a similar number of repeats as their
parental fibroblast (Figure S2E).
To examine the molecular basis for
the silencing of FMR1 transcription in
FX-iPSCs, we analyzed DNA methylation
level at the FMR1 promoter by using bisul-
fite treatment followed by pyrosequenc-
ing in fibroblasts and in their derived
iPSC lines. Pyrosequencing is an accu-
rate and reliable method to determine the
degree of methylation at several CpGs
in close proximity with high quantita-
tive resolution (Brakensiek et al., 2007;Cell Stem CDupont et al., 2004; Shaw et al., 2006;
Tost and Gut, 2007; Wong et al., 2006).
While the FMR1 locus consistently lacked
methylation in normal fibroblasts and their
derivative iPSC lines, 8 of 9 FX-iPSC
clones analyzed were highly methylated
at levels comparable to the original fibro-
blasts; one iPSC clone (FX-iPS A-52)
showed an intermediate methylation
level, but still much higher than the WT-
fibroblasts and iPSCs (Figure 2A). DNA
methylation at the FMR1 locus persisted
in the FX-iPSC clones despite the
complete lack of methylation at the pro-
moters for OCT4 (Figures 2B and 2C)ell 6, May 7, 2010 ª2010 Elsevier Inc. 409
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clones thus show a persistence of DNA
methylation at the FMR1 locus even after
reprogramming.
We further explored histone modifica-
tions associated with transcriptionally
active (H3 tail acetylation and lysine 4
methylation) and repressed (lysine 9
methylation) chromatin states associated
with FMR1 silencing in somatic cells
of FX individuals (Coffee et al., 1999,
2002; Pietrobono et al., 2005). We carried
out chromatin immunoprecipitation (ChIP)
experiments to analyze these modifica-
tions in two different FX-iPSC lines (#52
and #89). In contrast to the active chro-
matin marks on the FMR1 locus in
FX-ESCs, normal ESCs, and normal
iPSCs, the FMR1 locus in the FX-iPSCs
is methylated at H3K9 and lacks histone
acetylation and H3K4 methylation (Fig-
ure 2D). Our data suggest that in FX-
iPSCs, the mutated FMR1 gene has chro-
matin modifications that are consistent
with its transcriptionally silent state (see
Figure S2F).
Our results thus imply that the mutant
FMR1 locus in FX-iPSC lines is resistant
to activation by the iPSC reprogramming
protocol. Although reversion of aberrant
methylation, heterochromatin formation,
and loss of FMR1 expression has not
been studied during passage of the
mutant allele through the germline in
FRAXA families, conflicting data have
been reported for the capacity to reacti-
vate the silenced FMR1 gene in vitro.
Two groups have shown that transfer of
the X chromosome from FX patient cells
into mouse embryonal carcinoma cells
(Wo¨hrle et al., 2001) or fusion of FX cells
with normal fibroblasts (Stoyanova et al.,
2004) result in DNA demethylation and
reactivation of the FMR1 gene, whereas
a third group’s attempt to reactivate the
FMR1 gene by cell fusion with mouse
embryonic carcinoma cells failed to erase
the aberrant methylation of the mutant
FMR1 gene (Burman et al., 1999a). Simi-
larly, de novo methylation of an unmethy-
lated mutant FMR1 gene did not occur
when inserted via microcell-mediated
chromosome transfer into a mouse
embryonal carcinoma cell line (Burman
et al., 1999b). Treatment of somatic FX-
fibroblasts with the demethylating agent
5-azacytidine has been shown to reacti-
vate FMR1 expression (Tabolacci et al.,
2005). Apparently, under some circum-410 Cell Stem Cell 6, May 7, 2010 ª2010 Elsstances the epigenetic marks that main-
tain silencing of a mutant FMR1 gene
can be erased; however, the exact condi-
tions that enable the reactivation of the
FMR1 gene remain unclear. Although we
cannot exclude the possibility that repro-
gramming cells from a different tissue
or by a different method might reactivate
FMR1 gene expression over time in FX-
iPSCs, the FMR1 locus seems to be highly
resistant to the reprogramming process,
according to current standard practice.
Human ESCs and iPSCs offer signifi-
cant advantages for regenerative medi-
cine (Amabile and Meissner, 2009; Mu¨ller
et al., 2009; Nishikawa et al., 2008) and
the modeling of human genetic disorders
(Mu¨ller et al., 2009; Nishikawa et al.,
2008; Park et al., 2008a), although poten-
tial limitation such as chromosomal abnor-
malities (Baker et al., 2007; Lefort et al.,
2008; Maitra et al., 2005; Spits et al.,
2008) have to be considered before using
the cells as a disease model. Our data
highlight a significant difference between
FX-ESCs and FX-iPSCs with regard
to their expression of the FMR1 gene.
The mutated FMR1 gene is expressed in
FX-ESCs and transcriptionally silenced
upon differentiation, whereas in FX-iPSCs
the FMR1 locus remains inactive and is
not reset by the reprogramming process
to the transcriptionally active state. It is
thus possible that other disorders related
to epigenetic defects, including triplet
repeat and imprinting disorders, may like-
wise evade the reprogramming process.
Although FX-iPSCs do not model the
differentiation-dependent silencing of the
FMR1 gene, as shown for FX-ESCs, they
may remain valuable for analyzing the
role of FMR1 in neural cells. In FX-iPSCs,
like in FX-neurons and in contrast to
normal human iPSCs, the FMR1 gene is
methylated, its chromatin is in a closed
conformation, and the gene is not ex-
pressed. Therefore, differentiation of
FX-iPSCs into neurons may nonetheless
facilitate the study of FMR1 in neural
cells. Until a deeper understanding of
the potential differences between iPSCs
and ESCs is delineated, the study of
both iPSCs from patients and human
ESCs carrying the same mutation (either
from PGD embryos or by genetic manipu-
lation) might, whenever possible, be
the optimal approach to model human
genetic disorders through cell culture.
Finally, the distinction between FX-ESCsevier Inc.and FX-iPSCs at the FMR1 locus might
be a particular example of a more general
phenomenon of epigenetic differences
between human ESCs and iPSCs, which
highlights the need for more studies
to clarify the similarity and differences
between ESCs and iPSCs.
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